Publication | Open Access
Immunogenicity of an adalimumab biosimilar, FKB327, and its reference product in patients with rheumatoid arthritis
13
Citations
16
References
2020
Year
The RP and F showed comparable immunogenicity characteristics after long-term administration. Development of ADAs with the RP and F was similar, and was not impacted by switching and double switching between F and RP treatment.
| Year | Citations | |
|---|---|---|
Page 1
Page 1